Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics reported positive Phase 1a clinical data for RT-114, an oral biologic delivery candidate demonstrating bioavailability exceeding subcutaneous dosing. The company expanded its obesity pipeline through a new collaboration with PegBio, completed a $20 million stock offering, and strengthened its leadership team. Financial results sho…